Business Wire

Elisa and Vecima Supercharge Cable Network with DAA to Deliver Gigabit Access to Subscribers in Finland

Share

Vecima Networks Inc. (TSX: VCM) announced today that leading Finnish telecommunications operator Elisa has deployed Vecima’s EntraTM Remote MACPHY solution to evolve its network with a next-generation Distributed Access Architecture (DAA). The solution enables Elisa to deploy gigabit broadband and new service experiences to residential subscribers – detached homes and multi-dwelling units – and businesses. In addition, moving to DAA delivers sustainability through digitalization, enabling substantial energy savings.

In Finland’s highly competitive broadband market, Elisa brings highly innovative solutions to its subscribers. Vecima’s Entra DAA solution boasts flexible access node configurations, a cloud-based access controller, multiple video delivery options, and highly scalable capacity. As Elisa looks to maintain its market-leading position, Entra is well matched to forward-looking, strategic architectural plans.

“We are committed to offering our customers the best possible internet experience,” said Antti Salonen, Head of Technology for Fixed Networks at Elisa. “By deploying the Entra solution, we can move our cable access network to the next generation with higher capacity, new service offerings and automated network operations. Vecima’s unique DAA solution provides a flexible and efficient way to leverage our existing IP network to expand to new areas without the increased costs of additional headend equipment.”

To take advantage of untapped, latent capacity in Hybrid Fiber Coax (HFC) networks, the cable access network must be rearchitected and simplified to eliminate analog/RF transmission, replace, or digitize legacy video, and optimize operational costs. Once deployed, a Distribution Access Architecture increases network capacity and performance, lowers total cost of ownership, and reduces power consumption.

The Vecima SC-1D Entra Access Node offers a Remote MACPHY Device in a compact, European form factor. Elisa will deploy the SC-1D managed by the Vecima Entra Access Controller (EAC), which provides centralized control and leverages software-defined networking principles to pave the way for a platform capable of delivering faster connections to end users.

‟As cable operators contend with changes in the competitive landscape, and ever-growing demands for greater capacity and performance, we see growing momentum in the move to DAA,” said Ryan Nicometo, Senior Vice President and General Manager of Vecima’s Video & Broadband Solutions business. “Elisa is building one of the most innovative DAA deployments in the world, and we’re proud to help enable their strategic vision.”

Further information about Vecima’s Entra solution is available at vecima.com/solutions/distributed-access.

About Elisa

Elisa’s mission is a sustainable future through digitalisation. We are a pioneer in telecommunications and digital services, and in 5G. We provide sustainable solutions for over 2.8 million consumer, corporate and public administration customers in our core markets of Finland and Estonia, as well as in over 100 countries internationally. In Finland, Elisa is a market leader in telecommunications, and our international cooperation partners include Vodafone and Tele2. Elisa is listed on the Nasdaq Helsinki. In 2021, our revenue was EUR 2 billion and we employed 5,300 people in more than 20 countries. Elisa is a carbon-neutral company. Learn more at elisa.com

About Vecima Networks

Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive.

Learn more at vecima.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations
250-881-1982
invest@vecima.com

Media Relations
bernadette.dunn@vecima.com
david.slovensky@vecima.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye